The phase in clinical research, which leads to the generation of high-quality, error-free, statistically sound data derived from clinical trials, is termed as clinical data management (CDM). The CDM team is responsible for keeping track of all the processes involved in clinical trials- from inception to completion.
In order to reach to a high-quality, error-free clinical trial, and reliable analysis, the CDM team usually adopts software applications that maintain audit trail and provide easy identification and resolution of data discrepancies. These software tools that are used for data management are referred to as Clinical Data Management Systems (CDMS). CDMS enables handling of huge amount of data. The CDM tools that are most commonly used are ORACLE CLINICAL, CLINTRIAL, MACRO, RAVE, and eClinical Suite. Functionally, these tools are in no way superior to each other. Also, custom-made CDM tools like OpenClinica, openCDMS, TrialDB and PhOSCo are used by giant multinational pharmaceuticals depending upon their operational and procedural needs.
As a clinical trial is designed to answer a research question, the CDM process is designed to deliver an error-free database. To reach this, the CDM undergoes several processes:
Reviewing and finalizing of study documents
Case report form(CRF) tracking
Data entry and validation
CDM is the result of the increasing demand of the pharmaceutical MNCs to speed-up the drug development process. Maintaining a balance between the expectations and constraints in the existing system, CDM is becoming a standard clinical research entity.
White Paper By: Nous Infosystems
With the increasing need for business data analytics, healthcare payers must plan and implement solutions that make secondary use/re-use of data which is already available in various applications. This whitepaper to get an overview of the different sources of data, that payer systems can consider, advancements in bigdata, the challenges encountered, opportunities presented and listing of...
White Paper By: GSI Health
Value-based care is a kind of model in which providers are paid for keeping patients well (fee-for-value), not for the number of services they perform (fee-for-service). Integrating healthcare coordination with robust analytics into a single platform provides the big picture of patient care, enabling efficient, collaborative care for diverse teams to treat complex populations. This...
White Paper By: Data In Science Technologies
Leveraging the DataLogger for Metadata Cataloging establishes a singular view of the meaningful attributes for your data and identifies access rights to this data. Data in Science Technologies is proposing the concept of a central Data Catalog called DataLogger, analyzes identified data sets and extracts the metadata into a searchable catalog. Read this informative whitepaper to learn...
White Paper By: SHYFT Analytics, Inc.
Why Real World Evidence (RWE) is important to drive improvements in patient outcomes? Real World Evidence (RWE) has long been heralded as a “game changer” for the life sciences industry. Real World Evidence is the term used to describe research findings that use data that is gathered outside of standard clinical trials. This informative whitepaper highlights the...
White Paper By: Pacific Biomarkers
Preanalytical considerations in the design of clinical trials and epidemiologic studies are the cornerstones of the biochemical analyses. The main subject of clinical study design and epidemiology research is to monitor health, detect the harmful side effects and study the impact of therapeutic interventions. However, the largest contribution of errors in the clinical study design and...
Integrating FDA GLP Compliant Capabilities into a CAP/Clinical Trials Production Laboratory: An Alternate Approach
White Paper By: Pacific Biomarkers
Good Laboratory Practices (GLP): In order to enhance patient safety and improve the quality of testing performed in laboratories, there is a need for integrating good laboratory practices. There are many areas and processes that a laboratory should consider before adding waived testing to the panel of services. Incorporating FDA GLP capabilities into CAP/clinical facility poses...